Borrelia, Lyme
Conditions
Interventions
Arm 1: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks.
Arm 2: After open-label i.v. ceftriaxone 2000
Sponsors
University Medical Center St Radboud
Eligibility
Inclusion criteria
Inclusion criteria: 1. Males or non-pregnant, non-lactating females who are 18 years or older; 2. Women of child-bearing potential must agree to use contraception methods other than oral contraceptives during the study therapy period, since failure of oral contraceptives due to long-term antibiotic use has been described and doxycycline might be teratogenic; 3. Patients with presumed or proven PLD. In this study, clinical suspicion of PLD is defined as complaints of musculoskeletal pain, arthritis or arthralgia, neuralgia or sensory disturbances (such as paraesthesias or dysesthesias), neuropsychological or cognitive disorders, and persistent fatigue, that are: temporally related to an episode of erythema migrans or otherwise proven symptomatic Lyme disease (defined as within 4 months after erythema migrans as assessed by a physician, or positive biopsy, PCR, culture, intrathecal B. burgdorferi antibodies), OR accompanied by a positive B. burgdorferi IgG or IgM immunoblot (as defined by strict criteria in line with the European Union Concerted Action on Lyme Borreliosis (EUCALB)), regardless of prior ELISA IgG/IgM screening results; 4. Subjects must sign a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. Subjects with a known history of allergy or intolerance to tetracyclines, macrolides, hydroxychloroquine or ceftriaxone; 2. Subjects who have had more than 5 days of antimicrobial therapy with activity against B. burgdorferi within the previous 4 weeks; 3. Subjects with a presumed diagnosis of neuroborreliosis (CSF pleiocytosis or intrathecal antibody production) for which intravenous antimicrobial therapy is required; 4. Subjects with a known diagnosis of HIV-seropositivity or other immune disorders. (No HIV serologic testing is required for the study); 5. Subjects with positive syphilis serology or signs of other spirochetal diseases; 6. Subjects with moderate or severe liver disease defined as alkaline phosphatase, ALAT, or ASAT greater than 3 times upper limit of normal; 7. Subjects who are receiving and cannot discontinue cisapride, astemizole, terfenadine, barbiturates, phenytoin, or carbamazepine (The concentrations of these drugs may increase during clarithromycin therapy and/or lead to reduced availability of doxycycline); 8. Subjects who are currently enrolled on other investigational drug trials or receiving investigational agents; 9. Subjects who have been previously randomized into this study; 10. Severe physical or psychiatric co-morbidity that interferes with participation in the study protocol, including previous medical diagnosis of rheumatic conditions, chronic fatigue syndrome or chronic pain conditions as well as insufficient command of the Dutch language; 11. Co-morbidity that could (partially) account for the symptoms of the subject (e.g. vitamin B12 deficiency, anemia, hypothyroidism).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Because different operationalizations of the term ‘Global score 36-item Short-form General Health Survey (SF 36)’ exist, the primary outcome measure is specified here as the ‘physical component summary score’ (PCS) of the RAND-36 Health Status Inventory (RAND SF-36, Hays 1998), which is similar to the Medical Outcomes Study (MOS) 36-item Short-Form General Health Survey (SF-36). The PCS is also known as the physical health composite score (PHC). This specification has been communicated to the local Ethics Committee on March 1, 2011, and was approved on April 6, 2011. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Subscales 36-item Short-form General Health Survey (SF 36). Time Frame: Weeks 0, 14, 26 and 40; 2. Actometer recording during 14 days (objective physical activity). Time Frame: Weeks 0, 14 and 40; 3. Measurements of neuropsychological impairment. Time Frame: Weeks 0, 14, 26 and 40; 4. Economic evaluation: Questionaire EQ-5D, health consumption and productivity of labour. Time Frame: Weeks 0, 14, 26 and 40; 5. Fatigue subscale of Checklist Individual Strength (CIS). Time Frame: Weeks 0, 14, 26, and 40. After the last comprehensive outcome assessment at week 40, patients are surveyed by post-study questionnaires at week 52, regarding Subscales of 36-item Short-form General Health Survey, Economic evaluation and Fatigue subscale of Checklist Individual Strength. (Protocol version 3.8; dated July 17, 2009; final Ethics Committee approval April 29, 2010). | — |
Contacts
Public ContactA. Berende
Postbus 9101, Postnummer 463
Outcome results
None listed